|
Press Releases |
|
 |
|
Friday, September 9, 2022 |
|
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines |
PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing process of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
Tuesday, July 19, 2022 |
|
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. more info >> |
|
Thursday, February 17, 2022 |
|
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years) |
Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 ug dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. more info >> |
|
Wednesday, February 16, 2022 |
|
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries |
Moderna, Inc., (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 8, 2025 19:40 HKT/SGT
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 8, 2025 19:20 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 21:26: JST
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 7, 2025 20:31: JST
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 7, 2025 19:24 HKT/SGT
|
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 7, 2025 19:16 HKT/SGT
|
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 7, 2025 18:28 HKT/SGT
|
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 7, 2025 18:10 HKT/SGT
|
|
|
東信營銷科技:中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證
Mar 7, 2025 17:58 HKT/SGT
|
|
|
东信营销科技:中国AI营销龙头斩获多模态双备案 技术实力获国家级认证
Mar 7, 2025 17:20 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 7, 2025 16:24 JST
|
|
|
Giftify, Inc. Launches Sports Ticket & Merchandise Savings Platform as Fan Expenses Surge
Mar 7, 2025 15:02 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Collaboration with Her Excellency Sheikha Sara Nasser Al-Thani CEO of Qmission W.L.L. Qatar
Mar 7, 2025 14:47 HKT/SGT
|
|
|
Singapore to Host the 24th Cyber Security Summit: Addressing Emerging Threats and AI-Driven Security
Mar 7, 2025 14:40 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|